Cyteir Therapeutics, Inc. CYT
We take great care to ensure that the data presented and summarized in this overview for Cyteir Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CYT
Top Purchases
Top Sells
About CYT
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Insider Transactions at CYT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 20
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
170,589
+4.46%
|
$341,178
$2.95 P/Share
|
|
Mar 18
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
113,777
+3.16%
|
$341,331
$3.01 P/Share
|
|
Mar 04
2024
|
Markus Md Renschler President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,304
+0.57%
|
$6,304
$1.69 P/Share
|
|
Mar 04
2024
|
David G Gaiero Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,373
+2.27%
|
$2,373
$1.69 P/Share
|
|
Feb 29
2024
|
Markus Md Renschler President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,144
+0.68%
|
$15,144
$1.45 P/Share
|
|
Feb 29
2024
|
David G Gaiero Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,985
+3.91%
|
$7,985
$1.69 P/Share
|
|
Feb 14
2024
|
Jean George Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,150
+50.0%
|
$14,150
$1.69 P/Share
|
|
Feb 09
2024
|
Stephen H. Sands Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,129
+50.0%
|
$12,129
$1.69 P/Share
|
|
Feb 08
2024
|
John F Thero Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,828
+35.98%
|
$12,828
$1.69 P/Share
|
|
Feb 06
2024
|
Joseph S Zakrzewski Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,150
+5.86%
|
$14,150
$1.69 P/Share
|
|
Dec 11
2023
|
David G Gaiero Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,993
+2.14%
|
$3,993
$1.69 P/Share
|
|
Nov 20
2023
|
Markus Md Renschler President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
93,477
+2.12%
|
$93,477
$1.45 P/Share
|
|
Nov 20
2023
|
David G Gaiero Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
73,940
+31.81%
|
$73,940
$1.69 P/Share
|
|
Jul 20
2023
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
100,000
-2.76%
|
$200,000
$2.75 P/Share
|
|
Jul 19
2023
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,900
-0.05%
|
$3,800
$2.76 P/Share
|
|
Jul 18
2023
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
6,500
-0.18%
|
$13,000
$2.76 P/Share
|
|
Jul 17
2023
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
21,100
-0.58%
|
$42,200
$2.75 P/Share
|
|
Jul 14
2023
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
11,000
-0.3%
|
$22,000
$2.74 P/Share
|
|
Jun 30
2023
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
200,937
-5.2%
|
$401,874
$2.63 P/Share
|
|
Jun 27
2023
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
31,978
-0.82%
|
$31,978
$1.77 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 284K shares |
|---|---|
| Exercise of conversion of derivative security | 256K shares |